EPS

Brookfield is consolidating its corporate and wealth arms into one entity, a strategic move aimed at simplifying its structure for investors and fueling growth.

A top financial forum is urging a GST hike, corporate tax cuts, and a radical revamp of retirement savings in its bold 2026 federal budget proposal.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

Merchants Bancorp declared its Q2 dividends, underscoring financial health. The move comes as the bank navigates a complex market and legal scrutiny.

After unprecedented growth, Clear Fork Bank names a new CEO known for community ties, signaling a strategy to blend legacy values with future expansion.

After a record 2025, investors are watching if UP Fintech can sustain its growth amid global market turmoil and rising interest rates.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

Hormel Foods declared its 392nd dividend, but a high payout ratio and lagging stock have investors weighing its legendary reliability against current risks.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

With a key earnings report and investor conference ahead, all eyes are on Ulta Beauty to prove its resilience in a rapidly evolving retail landscape.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

The Chinese gaming giant signals confidence with a major share repurchase, but is it a growth strategy or a defensive play in a challenging market?

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

Following a blockbuster first quarter and raised guidance, Ralliant's CEO and CFO are set to detail their growth strategy at key investor conferences.

The biotech firm raises cash via a complex warrant deal, diluting shares to fund its promising but challenging RNAi therapy for deadly KRAS-driven cancers.

Wall Financial renews its significant share buyback plan, signaling confidence. But does it mask deeper concerns about debt and a volatile real estate market?

The chip equipment giant posts record Q2 revenue and profit, driven by surging AI demand, and unveils major partnerships to accelerate future tech.

With five years of record revenue, all eyes are on Build-A-Bear's upcoming Q1 results to see if its 'retailtainment' model can defy market headwinds.